Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy

被引：1
|
作者：
Barker, Kenneth [1 ]
Koza, Shannon [2 ]
Katsanis, Emmanuel [2 ,3 ,4 ,5 ,6 ]
Husnain, Muhammad [1 ,2 ]
机构：
[1] Univ Arizona, Dept Med, Tucson, AZ 85721 USA
[2] Univ Arizona, Canc Ctr, Tucson, AZ USA
[3] Univ Arizona, Dept Immunobiol, Tucson, AZ USA
[4] Univ Arizona, Dept Med, Tucson, AZ USA
[5] Univ Arizona, Dept Pathol, Tucson, AZ USA
[6] Univ Arizona, Dept Pediat, Tucson, AZ USA
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / 11期
关键词：
CYTOKINE RELEASE SYNDROME; ANGIOPOIETIN-1;
D O I：
10.1038/s41409-023-02083-4
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：1267 / 1269
页数：3
相关论文
共 50 条
  • [1] Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy
    Kenneth Barker
    Shannon Koza
    Emmanuel Katsanis
    Muhammad Husnain
    [J]. Bone Marrow Transplantation, 2023, 58 : 1267 - 1269
  • [2] Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy
    Winkelmann, Michael
    Blumenberg, Viktoria
    Rejeski, Kai
    Quell, Christina
    Buecklein, Veit L.
    Ingenerf, Maria
    Unterrainer, Marcus
    Schmidt, Christian
    Dekorsy, Franziska J.
    Bartenstein, Peter
    Ricke, Jens
    von Bergwelt-Baildon, Michael
    Subklewe, Marion
    Kunz, Wolfgang G.
    [J]. ANNALS OF HEMATOLOGY, 2024, 103 (01) : 259 - 268
  • [3] Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy
    Michael Winkelmann
    Viktoria Blumenberg
    Kai Rejeski
    Christina Quell
    Veit L. Bücklein
    Maria Ingenerf
    Marcus Unterrainer
    Christian Schmidt
    Franziska J. Dekorsy
    Peter Bartenstein
    Jens Ricke
    Michael von Bergwelt-Baildon
    Marion Subklewe
    Wolfgang G. Kunz
    [J]. Annals of Hematology, 2024, 103 : 259 - 268
  • [4] Hypophosphatemia and thrombocytopenia: A retrospective chart review to identify markers for prediction of CRS and ICANS in CAR T-cell therapy.
    Barker, Kenneth
    Bertolo, Aaron
    Uhland, Cole
    Koza, Shannon
    Katsanis, Emmanuel
    Husnain, Muhammad
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
    Vipul S Sheth
    Jordan Gauthier
    [J]. Bone Marrow Transplantation, 2021, 56 : 552 - 566
  • [6] Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
    Sheth, Vipul
    Gauthier, Jordan
    [J]. BONE MARROW TRANSPLANTATION, 2021, 56 (03) : 552 - 566
  • [7] How I treat refractory CRS and ICANS after CAR T-cell therapy
    Jain, Michael D.
    Smith, Melody
    Shah, Nirali N.
    [J]. BLOOD, 2023, 141 (20) : 2430 - 2442
  • [8] Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies
    Agarwal, Vibhu
    Aptekar, Jacob
    Fajgenbaum, David C.
    Lafeuille, Penelope
    [J]. BLOOD, 2022, 140 : 7838 - 7839
  • [9] Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy
    Gazeau, Nicolas
    Barba, Pere
    Iacoboni, Gloria
    Kwon, Mi
    Bailen, Rebeca
    Luis Reguera, Juan
    Lopez Corral, Lucia
    Hernani, Rafael
    Ortiz-Maldonado, Valentin
    Perez-Martinez, Antonio
    Maziarz, Richard T.
    Williamson, Staci
    Nemecek, Eneida R.
    Shadman, Mazyar
    Coman, Andrew
    Green, Damian J.
    Chow, Victor A.
    Hirayama, Alexandre V.
    Maloney, David G.
    Turtle, Cameron J.
    Gauthier, Jordan
    [J]. BLOOD, 2021, 138
  • [10] Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy
    Huang, Ivan J.
    Yeh, Rosa
    Sweiss, Karen
    Patel, Pritesh
    Hirayama, Alexandre Vinaud
    Kimble, Erik L.
    Juluri, Krishna R.
    Shadman, Mazyar
    Turtle, Cameron J.
    Maloney, David G.
    Gauthier, Jordan
    [J]. BLOOD, 2022, 140 : 12725 - 12727
12345